We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Consensus vs. actual, and revenue trend
Consensus PT $29.79 · 14 analysts
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Stored first · Google News · Yahoo Finance (English)
EBIT per share of Elanco Animal Health, Inc. – LS:A2N6BH - TradingView
EBIT per share of Elanco Animal Health, Inc. – LS:A2N6BH TradingView
Barclays Maintains Elanco Animal Health(ELAN.US) With Buy Rating, Maintains Target Price $30 - 富途牛牛
Barclays Maintains Elanco Animal Health(ELAN.US) With Buy Rating, Maintains Target Price $30 富途牛牛
Barclays Maintains Elanco Animal Health(ELAN.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Barclays Maintains Elanco Animal Health(ELAN.US) With Buy Rating, Maintains Target Price $30 Moomoo
A Look At Elanco Animal Health (ELAN) Valuation As Befrena Launch Expands Pet Dermatology Portfolio - simplywall.st
A Look At Elanco Animal Health (ELAN) Valuation As Befrena Launch Expands Pet Dermatology Portfolio simplywall.st
A Look at Elanco Animal Health Inc (ELAN) After 3.8% Gain -- GF Value $15.53 vs Price $23.69 - GuruFocus
A Look at Elanco Animal Health Inc (ELAN) After 3.8% Gain -- GF Value $15.53 vs Price $23.69 GuruFocus
Elanco (NYSE: ELAN) investors reelect board and ratify 2026 auditor - Stock Titan
Elanco (NYSE: ELAN) investors reelect board and ratify 2026 auditor Stock Titan
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 08. 06. | After market close (AMC) | $0.27 | — | — | $1.31B | — | Scheduled |
| FY2026 Q1 | 2025. 03. 31. | Time TBD | — | $0.13 | — | — | $1.19B | Reported |
| FY2025 Q3 | 2024. 09. 30. | Time TBD | — | $0.7 | — | — | $3.42B | Reported |
| FY2025 Q2 | 2024. 06. 30. | Time TBD | — | $-0.04 | — | — | $2.39B | Reported |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2026. 05. 08. | Citigroup | — | Maintain | Buy → Buy | — | Citigroup: Buy |
| 2026. 05. 08. | JP Morgan | — | Maintain | Overweight → Overweight | — | JP Morgan: Overweight |
| 2026. 04. 16. | Citigroup | — | Initiate coverage | — → Buy | — | Citigroup: Buy |
| 2026. 02. 26. | Morgan Stanley | — | Maintain | Equal-Weight → Equal-Weight | — | Morgan Stanley: Equal-Weight |
| 2026. 02. 25. | Keybanc | — | Maintain | Overweight → Overweight | — | Keybanc: Overweight |
| 2026. 02. 25. | Leerink Partners | — | Maintain | Outperform → Outperform | — | Leerink Partners: Outperform |
As of FY2026Q1 · Source: SEC/DART + price data
No holdings data to show.